サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：アレルギー性鼻炎治療薬市場：2024-2034年
市場調査レポート
商品コード
1424908

アレルギー性鼻炎治療薬市場：2024-2034年

Allergic Rhinitis Drugs Market Report 2024-2034
出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 322 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=198.76円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

アレルギー性鼻炎治療薬市場：2024-2034年
出版日: 2024年02月12日
発行: Visiongain Reports Ltd.
ページ情報: 英文 322 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のアレルギー性鼻炎治療薬の市場規模は、2034年にかけてCAGR 2.7%で成長すると予測されています。

花粉症とも呼ばれるアレルギー性鼻炎は、何百万人もの人々に影響を与え、生活の質全体に大きな影響を与える世界の問題として増加の一途をたどっています。アレルギー性鼻炎の有病率の増加は医療費の急増につながり、重要な市場促進要因として浮上しています。

アレルギー性鼻炎に関連する症状の緩和を目的とした医薬品に対する製薬業界の需要は顕著に増加しています。抗ヒスタミン剤、充血除去剤、コルチコステロイド、アレルギー免疫療法は、広く処方されている医薬品のひとつであり、アレルギー治療薬市場の活況に貢献しています。また、アレルギー性鼻炎の症状を緩和するために設計された点鼻スプレーやその他の医療機器も人気を得ています。これらは症状管理のための非薬理学的方法を提供し、最先端技術の市場の拡大を生み出しています。

当レポートでは、世界のアレルギー性鼻炎治療薬の市場を調査し、市場概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な調査結果
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
  • COVID-19の影響分析
  • ポーターのファイブフォース分析
  • PEST分析

第4章 アレルギー性鼻炎治療薬市場の分析：治療タイプ別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 抗ヒスタミン薬
  • 免疫療法
  • コルチコステロイド
  • 鼻詰まり除去剤
  • その他
    • 市場規模の推移・予測：地域別
    • 市場シェア：地域別

第5章 アレルギー性鼻炎治療薬市場の分析：疾患別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 季節性アレルギー性鼻炎
  • 通年性アレルギー性鼻炎
  • 職業性アレルギー性鼻炎
    • 市場規模の推移・予測：地域別
    • 市場シェア：地域別

第6章 アレルギー性鼻炎治療薬市場の分析：薬剤タイプ別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 処方箋
  • OTC
    • 市場規模の推移・予測：地域別
    • 市場シェア：地域別

第7章 アレルギー性鼻炎治療薬市場の分析：投与経路別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 経口
  • 経鼻
  • 眼内
  • 静脈内
    • 市場規模の推移・予測：地域別
    • 市場シェア：地域別

第8章 アレルギー性鼻炎治療薬市場の分析：流通チャネル別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 小売薬局
  • 病院薬局
  • オンラインチャネル
    • 市場規模の推移・予測：地域別
    • 市場シェア：地域別

第9章 アレルギー性鼻炎治療薬市場の分析：地域別

  • 主要調査結果
  • 市場規模の推移・予測

第10章 北米のアレルギー性鼻炎治療薬市場の分析

第11章 欧州のアレルギー性鼻炎治療薬市場の分析

第12章 アジア太平洋のアレルギー性鼻炎治療薬市場の分析

第13章 ラテンアメリカのアレルギー性鼻炎治療薬市場の分析

第14章 中東・アフリカのアレルギー性鼻炎治療薬市場の分析

第15章 企業プロファイル

  • 競合情勢
  • 戦略的展望
  • Alcon
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • GSK plc
  • Johnson &Johnson Services, Inc.
  • Merck &Co., Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

第16章 総論・推奨事項

  • Visiongainによる総論
  • 参入企業への推奨事項
図表

List of Tables

  • Table 1 Allergic Rhinitis Drugs Snapshot, 2024 & 2034 (US$ Million, CAGR %)
  • Table 2 Increasing Prevalence of Respiratory Disorders
  • Table 3 Allergic Rhinitis Drugs Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 4 Allergic Rhinitis Drugs Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 5 Allergic Rhinitis Drugs Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 6 Allergic Rhinitis Drugs Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 7 Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 8 Antihistamines Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 9 Immunotherapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 10 Subcutaneous Immunotherapy (SCIT) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 11 Sublingual Immunotherapy (SLIT) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 12 Corticosteroids Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 13 Decongestants Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 14 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 15 Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 16 Seasonal Allergic Rhinitis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 17 Perennial Allergic Rhinitis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 18 Occupational Allergic Rhinitis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 19 Allergic Rhinitis Drugs Drug Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 20 Prescription Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 21 OTC Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 22 Allergic Rhinitis Drugs by Route of Administration 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 23 Oral Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 24 Nasal Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 25 Intraocular Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 26 Intravenous Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 27 Allergic Rhinitis Drugs Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 28 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 29 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 30 Online Channels Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 31 Allergic Rhinitis Drugs Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 32 North America Allergic Rhinitis Drugs Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 33 North America Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 34 North America Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 35 Allergic Rhinitis Drug, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 36 North America Allergic Rhinitis Drugs by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 37 North America Allergic Rhinitis Drugs by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 38 U.S. Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 39 Canada Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 40 Europe Allergic Rhinitis Drugs Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 41 Europe Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 42 North America Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 43 Allergic Rhinitis Drugs by Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 44 North America Allergic Rhinitis Drugs by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 45 North America Allergic Rhinitis Drugs by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 46 Germany Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 47 France Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 48 UK Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 49 Italy Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 50 Spain Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 51 Russia Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 52 Poland Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 53 Belgium Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 54 Rest of Europe Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 55 Asia Pacific Allergic Rhinitis Drugs Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 56 Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 57 North America Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 58 Allergic Rhinitis Drugs by Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 59 North America Allergic Rhinitis Drugs by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 60 North America Allergic Rhinitis Drugs by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 61 Japan Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 62 China Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 63 India Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 64 Australia Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 65 South Korea Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 66 Singapore Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 67 Taiwan Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 68 Rest of Asia Pacific Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 69 Latin America Allergic Rhinitis Drugs Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 70 Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 71 North America Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 72 Allergic Rhinitis Drugs by Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 73 North America Allergic Rhinitis Drugs by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 74 North America Allergic Rhinitis Drugs by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 75 Brazil Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 76 Mexico Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 77 Argentina Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 78 Rest of Latin America Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 79 MEA Allergic Rhinitis Drugs Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 80 Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 81 North America Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 82 Allergic Rhinitis Drugs by Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 83 North America Allergic Rhinitis Drugs by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 84 North America Allergic Rhinitis Drugs by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 85 GCC Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 86 South Africa Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 87 Rest of MEA Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 88 Strategic Outlook
  • Table 89 Alcon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 Alcon: Product Benchmarking
  • Table 91 Alcon: Strategic Outlook
  • Table 92 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 AstraZeneca: Product Benchmarking
  • Table 94 AstraZeneca: Strategic Outlook
  • Table 95 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 Bayer AG: Product Benchmarking
  • Table 97 Bayer AG: Strategic Outlook
  • Table 98 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 Boehringer Ingelheim International GmbH: Product Benchmarking
  • Table 100 Dr. Reddy's Laboratories Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 101 Dr. Reddy's Laboratories Ltd: Product Benchmarking
  • Table 102 Dr. Reddy's Laboratories Ltd: Strategic Outlook
  • Table 103 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 104 GSK plc: Product Benchmarking
  • Table 105 GSK plc: Strategic Outlook
  • Table 106 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 107 Johnson & Johnson Services, Inc.: Product Benchmarking
  • Table 108 Johnson & Johnson Services, Inc.: Strategic Outlook
  • Table 109 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 110 Merck & Co., Inc.: Product Benchmarking
  • Table 111 Merck & Co., Inc.: Strategic Outlook
  • Table 112 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Sanofi: Product Benchmarking
  • Table 114 Sanofi: Strategic Outlook
  • Table 115 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Sun Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 117 Sun Pharmaceutical Industries Ltd.: Strategic Outlook
  • Table 118 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 119 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 120 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
  •  

List of Figures

  • Figure 1 Allergic Rhinitis Drugs Segmentation
  • Figure 2 Allergic Rhinitis Drugs Market by Treatment Type: Market Attractiveness Index
  • Figure 3 Allergic Rhinitis Drugs by Disease Type: Market Attractiveness Index
  • Figure 4 Allergic Rhinitis Drugs by Drug Type: Market Attractiveness Index
  • Figure 5 Allergic Rhinitis Drugs by Route of Administration: Market Attractiveness Index
  • Figure 6 Allergic Rhinitis Drugs by Distribution Channel: Market Attractiveness Index
  • Figure 7 Allergic Rhinitis Drugs Attractiveness Index by Region
  • Figure 8 Allergic Rhinitis Drugs: Market Dynamics
  • Figure 9 Allergic Rhinitis Drugs by Region, 2024-2034 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 10 Allergic Rhinitis Drugs by Region, 2024-2034 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 11 Allergic Rhinitis Drugs by Region, 2024-2034 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 12 Allergic Rhinitis Drugs by Region, 2024-2034 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 13 Allergic Rhinitis Drugs Market: Porter's Five Forces Analysis
  • Figure 14 Allergic Rhinitis Drugs: PEST Analysis
  • Figure 15 Allergic Rhinitis Drugs by Treatment Type: Market Attractiveness Index
  • Figure 16 Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR %)
  • Figure 17 Allergic Rhinitis Drugs Share Forecast by Treatment Type, 2024, 2029, 2034 (%)
  • Figure 18 Antihistamines Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 19 Antihistamines Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 20 Immunotherapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 21 Immunotherapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 22 Subcutaneous Immunotherapy (SCIT) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 23 Subcutaneous Immunotherapy (SCIT) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 24 Sublingual Immunotherapy (SLIT) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 25 Sublingual Immunotherapy (SLIT) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 26 Corticosteroids Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 27 Corticosteroids Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 28 Decongestants Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 29 Decongestants Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 30 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 31 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 32 Allergic Rhinitis Drugs by Disease Type: Market Attractiveness Index
  • Figure 33 Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR %)
  • Figure 34 Allergic Rhinitis Drugs Share Forecast by Disease Type, 2024, 2029, 2034 (%)
  • Figure 35 Seasonal Allergic Rhinitis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 36 Seasonal Allergic Rhinitis Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 Perennial Allergic Rhinitis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 38 Perennial Allergic Rhinitis Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 39 Occupational Allergic Rhinitis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 40 Occupational Allergic Rhinitis Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Allergic Rhinitis Drugs by Drug Type: Market Attractiveness Index
  • Figure 42 Allergic Rhinitis Drugs Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
  • Figure 43 Allergic Rhinitis Drugs Share Forecast by Drug Type, 2024, 2029, 2034 (%)
  • Figure 44 Prescription Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 45 Prescription Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 OTC Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 47 OTC Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Allergic Rhinitis Drugs by Route of Administration: Market Attractiveness Index
  • Figure 49 Allergic Rhinitis Drugs Forecast by Route of Admistration 2024-2034 (US$ Million, AGR %)
  • Figure 50 Allergic Rhinitis Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
  • Figure 51 Oral Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 52 Oral Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 53 Nasal Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 54 Nasal Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 55 Intraocular Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 56 Intraocular Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 57 Intravenous Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 58 Intravenous Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 59 Allergic Rhinitis Drugs by Distribution Channel: Market Attractiveness Index
  • Figure 60 Allergic Rhinitis Drugs Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 61 Allergic Rhinitis Drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 62 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 63 Retail Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 64 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 65 Retail Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 66 Online Channels Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 67 Online Channels Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 68 Allergic Rhinitis Drugs Forecast by Region 2023 and 2033 (Revenue, CAGR %)
  • Figure 69 Allergic Rhinitis Drugs Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 70 Allergic Rhinitis Drugs by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 71 North America Allergic Rhinitis Drugs Attractiveness Index
  • Figure 72 North America Allergic Rhinitis Drugs by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 73 North America Allergic Rhinitis Drugs Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 74 North America Allergic Rhinitis Drugs Share Forecast by Country, 2024 & 2034 (%)
  • Figure 75 North America Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR %)
  • Figure 76 North America Allergic Rhinitis Drugs Share Forecast by Treatment Type, 2024 & 2034 (%)
  • Figure 77 North America Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR %)
  • Figure 78 North America Allergic Rhinitis Drugs Share Forecast by Disease Type, 2024 & 2034 (%)
  • Figure 79 North America Allergic Rhinitis Drugs Forecast by Drug, 2024-2034 (US$ Million, AGR %)
  • Figure 80 North America Allergic Rhinitis Drugs Share Forecast by Drug, 2024 & 2034 (%)
  • Figure 81 North America Allergic Rhinitis Drugs Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 82 North America Allergic Rhinitis Drugs Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 83 North America Allergic Rhinitis Drugs Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 84 North America Allergic Rhinitis Drugs Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 85 U.S. Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 86 Canada Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 87 Europe Allergic Rhinitis Drugs Attractiveness Index
  • Figure 88 Europe Allergic Rhinitis Drugs by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 89 Europe Allergic Rhinitis Drugs Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 90 Europe Allergic Rhinitis Drugs Share Forecast by Country, 2024 & 2034 (%)
  • Figure 91 Europe Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR %)
  • Figure 92 Europe Allergic Rhinitis Drugs Share Forecast by Treatment Type, 2024 & 2034 (%)
  • Figure 93 Europe Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR %)
  • Figure 94 Europe Allergic Rhinitis Drugs Share Forecast by Disease Type, 2024 & 2034 (%)
  • Figure 95 Europe Allergic Rhinitis Drugs Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
  • Figure 96 Europe Allergic Rhinitis Drugs Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 97 Europe Allergic Rhinitis Drugs Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 98 Europe Allergic Rhinitis Drugs Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 99 Europe Allergic Rhinitis Drugs Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 100 Europe Allergic Rhinitis Drugs Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 101 Germany Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 102 France Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 103 UK Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 104 Italy Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 105 Spain Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 106 Russia Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 107 Poland Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 108 Belgium Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 109 Rest of Europe Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 110 Asia Pacific Allergic Rhinitis Drugs Attractiveness Index
  • Figure 111 Asia Pacific Allergic Rhinitis Drugs by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 112 Asia Pacific Allergic Rhinitis Drugs Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 113 Asia Pacific Allergic Rhinitis Drugs Share Forecast by Country, 2024 & 2034 (%)
  • Figure 114 Asia Pacific Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR %)
  • Figure 115 Asia Pacific Allergic Rhinitis Drugs Share Forecast by Treatment Type, 2024 & 2034 (%)
  • Figure 116 Asia Pacific Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR %)
  • Figure 117 Asia Pacific Allergic Rhinitis Drugs Share Forecast by Disease Type, 2024 & 2034 (%)
  • Figure 118 Asia Pacific Allergic Rhinitis Drugs Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
  • Figure 119 Asia Pacific Allergic Rhinitis Drugs Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 120 Asia Pacific Allergic Rhinitis Drugs Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 121 Asia Pacific Allergic Rhinitis Drugs Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 122 Asia Pacific Allergic Rhinitis Drugs Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 123 Asia Pacific Allergic Rhinitis Drugs Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 124 Japan Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 125 China Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 126 India Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 127 Australia Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 128 South Korea Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 129 Singapore Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 130 Taiwan Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 131 Rest of Asia Pacific Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 132 Latin America Allergic Rhinitis Drugs Attractiveness Index
  • Figure 133 Latin America Allergic Rhinitis Drugs by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 134 Latin America Allergic Rhinitis Drugs Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 135 Latin America Allergic Rhinitis Drugs Share Forecast by Country, 2024 & 2034 (%)
  • Figure 136 Latin America Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR %)
  • Figure 137 Latin America Allergic Rhinitis Drugs Share Forecast by Treatment Type, 2024 & 2034 (%)
  • Figure 138 Latin America Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR %)
  • Figure 139 Latin America Allergic Rhinitis Drugs Share Forecast by Disease Type, 2024 & 2034 (%)
  • Figure 140 Latin America Allergic Rhinitis Drugs Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
  • Figure 141 Latin America Allergic Rhinitis Drugs Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 142 Latin America Allergic Rhinitis Drugs Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 143 Latin America Allergic Rhinitis Drugs Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 144 Latin America Allergic Rhinitis Drugs Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 145 Latin America Allergic Rhinitis Drugs Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 146 Brazil Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 147 Mexico Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 148 Argentina Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 149 Rest of Latin America Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 150 MEA Allergic Rhinitis Drugs Attractiveness Index
  • Figure 151 MEA Allergic Rhinitis Drugs by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 152 MEA Allergic Rhinitis Drugs Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 153 MEA Allergic Rhinitis Drugs Share Forecast by Country, 2024 & 2034 (%)
  • Figure 154 MEA Allergic Rhinitis Drugs Forecast by Treatment Type, 2024-2034 (US$ Million, AGR %)
  • Figure 155 MEA Allergic Rhinitis Drugs Share Forecast by Treatment Type, 2024 & 2034 (%)
  • Figure 156 MEA Allergic Rhinitis Drugs Forecast by Disease Type, 2024-2034 (US$ Million, AGR %)
  • Figure 157 MEA Allergic Rhinitis Drugs Share Forecast by Disease Type, 2024 & 2034 (%)
  • Figure 158 MEA Allergic Rhinitis Drugs Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
  • Figure 159 MEA Allergic Rhinitis Drugs Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 160 MEA Allergic Rhinitis Drugs Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 161 MEA Allergic Rhinitis Drugs Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 162 MEA Allergic Rhinitis Drugs Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 163 MEA Allergic Rhinitis Drugs Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 164 GCC Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 165 South Africa Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 166 Rest of MEA Allergic Rhinitis Drugs Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 167 Allergic Rhinitis Drugs Market: Company Share, 2023
  • Figure 168 Alcon: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 169 Alcon: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 170 Alcon: Regional Market Shares, 2022
  • Figure 171 AstraZeneca: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 172 AstraZeneca: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 173 AstraZeneca: Regional Market Shares, 2022
  • Figure 174 Bayer AG: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 175 Bayer AG: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 176 Bayer AG: Regional Market Shares, 2022
  • Figure 177 Boehringer Ingelheim International GmbH: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 178 Boehringer Ingelheim International GmbH: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 179 Boehringer Ingelheim International GmbH: Regional Market Shares, 2022
  • Figure 180 Dr. Reddy's Laboratories Ltd: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 181 Dr. Reddy's Laboratories Ltd: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 182 Dr. Reddy's Laboratories Ltd: Regional Market Shares, 2022
  • Figure 183 GSK plc: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 184 GSK plc: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 185 GSK plc: Regional Market Shares, 2022
  • Figure 186 Johnson & Johnson Services, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 187 Johnson & Johnson Services, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 188 Johnson & Johnson Services, Inc.: Regional Market Shares, 2022
  • Figure 189 Merck & Co., Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 190 Merck & Co., Inc.: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 191 Merck & Co., Inc.: Regional Market Shares, 2022
  • Figure 192 Sanofi: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 193 Sanofi: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 194 Sanofi: Regional Market Shares, 2022
  • Figure 195 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 196 Sun Pharmaceutical Industries Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 197 Sun Pharmaceutical Industries Ltd.: Regional Market Shares, 2022
  • Figure 198 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 199 Teva Pharmaceutical Industries Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 200 Teva Pharmaceutical Industries Ltd.: Regional Market Shares, 2022
目次
Product Code: PHA1315

The global Allergic Rhinitis Drugs market is estimated to grow at a CAGR of 2.7% by 2034

The Allergic Rhinitis Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Prevalence of Allergic Rhinitis

Allergic rhinitis, often referred to as hay fever, is an increasing global issue that impacts millions of individuals, significantly influencing their overall quality of life. The increasing prevalence of allergic rhinitis has not only led to a surge in healthcare costs but has also emerged as a significant market driver.

There has been a notable increase in the pharmaceutical industry's demand for medications aimed at relieving symptoms associated with allergic rhinitis. Antihistamines, decongestants, corticosteroids, and allergy immunotherapy are among the widely prescribed drugs, contributing to a booming market for allergy medications. Nasal sprays and other medical devices designed to provide relief from allergic rhinitis symptoms have gained popularity. These devices provide a non-pharmacological method for symptom management, creating an expanding market for cutting-edge technologies.

The increasing prevalence of allergic rhinitis has led to a higher demand for healthcare services, including allergy testing and immunotherapy. Allergists, immunologists, and ENT specialists are witnessing an uptick in patient visits, driving growth in these medical fields. The rise of telemedicine has provided a convenient platform for allergic rhinitis patients to consult healthcare professionals remotely. This trend has not only improved access to care but has also contributed to the expansion of virtual healthcare services.

Growing Awareness and Diagnosis Driving Allergic Rhinitis Drugs Market

As information becomes more accessible, patients are increasingly becoming proactive advocates for their health. The internet, social media, and healthcare apps play a pivotal role in disseminating knowledge about various health conditions, symptoms, and preventive measures. This empowerment has led to a more informed patient population, actively participating in their healthcare decisions. Growing awareness has shifted the focus from reactive to proactive healthcare. Individuals are now more inclined towards preventive measures, including regular health check-ups, screenings, and lifestyle modifications. This shift has not only reduced the burden on healthcare systems but has also created new market opportunities for preventive healthcare services and products. The health and wellness industry is booming as people increasingly prioritize a holistic approach to well-being. From fitness trackers and nutrition apps to wellness retreats and personalized health plans, the market is witnessing unprecedented growth.

Individuals are prepared to invest in products and services that enhance their overall well-being and quality of life. The swift progress of diagnostic technologies has transformed the precision and efficiency of disease identification.

From genetic testing to advanced imaging techniques, these technologies enable early detection and personalized treatment plans, driving demand for diagnostic services and equipment.

The increasing comprehension of the genetic and molecular dimensions of diseases has opened the door to precision medicine. Customizing treatments based on individual genetic profiles enables more efficient and targeted interventions. This shift in paradigm is shaping pharmaceutical development, emphasizing personalized therapies. Greater awareness has resulted in a rise in the demand for regular screenings and early detection programs.

What Questions Should You Ask before Buying a Market Research Report?

How is the Allergic Rhinitis Drugs Market evolving?

What is driving and restraining the Allergic Rhinitis Drugs Market?

How will each Allergic Rhinitis Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Allergic Rhinitis Drugs submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Allergic Rhinitis Drugs Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Allergic Rhinitis Drugs projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Allergic Rhinitis

Drugs projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Allergic Rhinitis Drugs Market?

Where is the Allergic Rhinitis Drugs Market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Allergic Rhinitis Drugs Market today, and over the next 10 years:

Our 322-page report provides 120 tables and 200 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Allergic Rhinitis Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges) and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

By Treatment Type

Antihistamines

Immunotherapy: Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT)

Corticosteroids

Decongestants

Others

By Disease Type

Seasonal Allergic Rhinitis

Perennial Allergic Rhinitis

Occupational Allergic Rhinitis

By Drug

Prescription

OTC

By Route of Administration

Oral

Nasal

Intraocular

Intravenous

By Distribution channel

Hospital Pharmacies

Retail Pharmacies

Online channels

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 26 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Russia

Poland

Belgium

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Allergic Rhinitis Drugs Market 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Alcon

AstraZeneca

Bayer AG

Boehringer Ingelheim International GmbH

Dr. Reddy's Laboratories Ltd.

GSK plc

Johnson & Johnson Services, Inc.

Merck & Co., Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Overall world revenue for Allergic Rhinitis Drugs Market, 2024 to 2034 in terms of value the market will surpass US$16,800.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Allergic Rhinitis Drugs Market 2024 to 2034 report help you?

In summary, our 320+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Allergic Rhinitis Drugs Market 2024 to 2034 Market, with forecasts for product and application each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 26 key national markets - See forecasts for the Allergic Rhinitis Drugs Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 11 of the major companies involved in the Allergic Rhinitis Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Allergic Rhinitis Drugs Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Allergic Rhinitis Drugs
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Growing Awareness About Allergies and Available Treatment Options
      • 3.2.1.2 Increasing Prevalence of Respiratory Disorders
      • 3.2.1.3 Launch of Effective and Novel Drug Delivery Systems
      • 3.2.1.4 Technological Advancements
      • 3.2.1.5 Growing Pollution Levels Coupled with Rise in Respiratory Disorders
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Adverse Effects of Drugs Used in Treatment of Allergic Rhinitis
      • 3.2.2.2 Similarity of Symptoms with Other Diseases
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Increasing Advancements in Allergen Immunotherapy (AIT)
      • 3.2.3.2 Favourable Government Initiatives to Promote Awareness Regarding Allergic Rhinitis
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Allergic Rhinitis Drugs Analysis by Treatment Type

  • 4.1 Key Findings
  • 4.2 Treatment Type Segment: Market Attractiveness Index
  • 4.3 Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
  • 4.4 Antihistamines
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Immunotherapy
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
      • 4.5.2.1 Subcutaneous Immunotherapy (SCIT)
      • 4.5.2.2 Sublingual Immunotherapy (SLIT)
  • 4.6 Corticosteroids
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)
  • 4.7 Decongestants
    • 4.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.7.2 Market Share by Region, 2024 & 2034 (%)
  • 4.8 Others
    • 4.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.8.2 Market Share by Region, 2024 & 2034 (%)

5 Allergic Rhinitis Drugs Analysis by Disease Type

  • 5.1 Key Findings
  • 5.2 Disease Type Segment: Market Attractiveness Index
  • 5.3 Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
  • 5.4 Seasonal Allergic Rhinitis
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Perennial Allergic Rhinitis
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Occupational Allergic Rhinitis
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Allergic Rhinitis Drugs Analysis by Drug Type

  • 6.1 Key Findings
  • 6.2 Drug Type Segment: Market Attractiveness Index
  • 6.3 Allergic Rhinitis Drugs Size Estimation and Forecast by Drug Type
  • 6.4 Prescription
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 OTC
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Allergic Rhinitis Drugs Analysis by Route of Administration

  • 7.1 Key Findings
  • 7.2 Route of Administration Segment: Market Attractiveness Index
  • 7.3 Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
  • 7.4 Oral
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Nasal
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Intraocular
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)
  • 7.7 Intravenous
    • 7.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.7.2 Market Share by Region, 2024 & 2034 (%)

8 Allergic Rhinitis Drugs Analysis by Distribution Channel

  • 8.1 Key Findings
  • 8.2 Distribution Channel Segment: Market Attractiveness Index
  • 8.3 Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
  • 8.4 Retail Pharmacies
    • 8.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 8.4.2 Market Share by Region, 2024 & 2034 (%)
  • 8.5 Hospital Pharmacies
    • 8.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 8.5.2 Market Share by Region, 2024 & 2034 (%)
  • 8.6 Online Channels
    • 8.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 8.6.2 Market Share by Region, 2024 & 2034 (%)

9 Allergic Rhinitis Drugs Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Allergic Rhinitis Drugs Analysis

  • 10.1 Key Findings
  • 10.2 North America Allergic Rhinitis Drugs Attractiveness Index
  • 10.3 North America Allergic Rhinitis Drugs by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Country
  • 10.5 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
  • 10.6 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
  • 10.7 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Drug
  • 10.8 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
  • 10.9 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
  • 10.10 U.S. Allergic Rhinitis Drugs Analysis
  • 10.11 Canada Allergic Rhinitis Drugs Analysis

11 Europe Allergic Rhinitis Drugs Analysis

  • 11.1 Key Findings
  • 11.2 Europe Allergic Rhinitis Drugs Attractiveness Index
  • 11.3 Europe Allergic Rhinitis Drugs by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Country
  • 11.5 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
  • 11.6 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
  • 11.7 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Drug Type
  • 11.8 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
  • 11.9 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
  • 11.10 Germany Allergic Rhinitis Drugs Analysis
  • 11.11 France Allergic Rhinitis Drugs Analysis
  • 11.12 UK Allergic Rhinitis Drugs Analysis
  • 11.13 Italy Allergic Rhinitis Drugs Analysis
  • 11.14 Spain Allergic Rhinitis Drugs Analysis
  • 11.15 Russia Allergic Rhinitis Drugs Analysis
  • 11.16 Poland Allergic Rhinitis Drugs Analysis
  • 11.17 Belgium Allergic Rhinitis Drugs Analysis
  • 11.18 Rest of Europe Allergic Rhinitis Drugs Analysis

12 Asia Pacific Allergic Rhinitis Drugs Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Allergic Rhinitis Drugs Attractiveness Index
  • 12.3 Asia Pacific Allergic Rhinitis Drugs by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Country
  • 12.5 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
  • 12.6 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
  • 12.7 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Drug Type
  • 12.8 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
  • 12.9 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
  • 12.10 Japan Allergic Rhinitis Drugs Analysis
  • 12.11 China Allergic Rhinitis Drugs Analysis
  • 12.12 India Allergic Rhinitis Drugs Analysis
  • 12.13 Australia Allergic Rhinitis Drugs Analysis
  • 12.14 South Korea Allergic Rhinitis Drugs Analysis
  • 12.15 Singapore Allergic Rhinitis Drugs Analysis
  • 12.16 Taiwan Allergic Rhinitis Drugs Analysis
  • 12.17 Rest of Asia Pacific Allergic Rhinitis Drugs Analysis

13 Latin America Allergic Rhinitis Drugs Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Allergic Rhinitis Drugs Attractiveness Index
  • 13.3 Latin America Allergic Rhinitis Drugs by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Country
  • 13.5 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
  • 13.6 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
  • 13.7 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Drug Type
  • 13.8 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
  • 13.9 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
  • 13.10 Brazil Allergic Rhinitis Drugs Analysis
  • 13.11 Mexico Allergic Rhinitis Drugs Analysis
  • 13.12 Argentina Allergic Rhinitis Drugs Analysis
  • 13.13 Rest of Latin America Allergic Rhinitis Drugs Analysis

14 MEA Allergic Rhinitis Drugs Analysis

  • 14.1 Key Findings
  • 14.2 MEA Allergic Rhinitis Drugs Attractiveness Index
  • 14.3 MEA Allergic Rhinitis Drugs by Country, 2024, 2029 & 2034 (US$ Million)
  • 14.4 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Country
  • 14.5 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
  • 14.6 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
  • 14.7 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Drug Type
  • 14.8 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
  • 14.9 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
  • 14.10 GCC Allergic Rhinitis Drugs Analysis
  • 14.11 South Africa Allergic Rhinitis Drugs Analysis
  • 14.12 Rest of MEA Allergic Rhinitis Drugs Analysis

15 Company Profiles

  • 15.1 Competitive Landscape, 2023
  • 15.2 Strategic Outlook
  • 15.3 Alcon
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2017-2022
      • 15.3.3.2 R&D, 2017-2022
      • 15.3.3.3 Regional Market Shares, 2022
    • 15.3.4 Product Benchmarking
    • 15.3.5 Strategic Outlook
  • 15.4 AstraZeneca
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2017-2022
      • 15.4.3.2 R&D, 2017-2022
      • 15.4.3.3 Regional Market Shares, 2022
    • 15.4.4 Product Benchmarking
    • 15.4.5 Strategic Outlook
  • 15.5 Bayer AG
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2017-2022
      • 15.5.3.2 R&D, 2017-2022
      • 15.5.3.3 Regional Market Shares, 2022
    • 15.5.4 Product Benchmarking
    • 15.5.5 Strategic Outlook
  • 15.6 Boehringer Ingelheim International GmbH
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2017-2022
      • 15.6.3.2 R&D, 2017-2022
      • 15.6.3.3 Regional Market Shares, 2022
    • 15.6.4 Product Benchmarking
  • 15.7 Dr. Reddy's Laboratories Ltd.
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2017-2022
      • 15.7.3.2 R&D, 2017-2022
      • 15.7.3.3 Regional Market Shares, 2022
    • 15.7.4 Product Benchmarking
    • 15.7.5 Strategic Outlook
  • 15.8 GSK plc
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2017-2022
      • 15.8.3.2 R&D, 2017-2022
      • 15.8.3.3 Regional Market Shares, 2022
    • 15.8.4 Product Benchmarking
    • 15.8.5 Strategic Outlook
  • 15.9 Johnson & Johnson Services, Inc.
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Financial Analysis
      • 15.9.3.1 Net Revenue, 2017-2022
      • 15.9.3.2 R&D, 2017-2022
      • 15.9.3.3 Regional Market Shares, 2022
    • 15.9.4 Product Benchmarking
    • 15.9.5 Strategic Outlook
  • 15.10 Merck & Co., Inc.
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2017-2022
      • 15.10.3.2 R&D, 2017-2022
      • 15.10.3.3 Regional Market Shares, 2022
    • 15.10.4 Product Benchmarking
    • 15.10.5 Strategic Outlook
  • 15.11 Sanofi
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2017-2022
      • 15.11.3.2 R&D, 2017-2022
      • 15.11.3.3 Regional Market Shares, 2022
    • 15.11.4 Product Benchmarking
    • 15.11.5 Strategic Outlook
  • 15.12 Sun Pharmaceutical Industries Ltd.
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 Net Revenue, 2017-2022
      • 15.12.3.2 R&D, 2017-2022
      • 15.12.3.3 Regional Market Shares, 2022
    • 15.12.4 Product Benchmarking
    • 15.12.5 Strategic Outlook
  • 15.13 Teva Pharmaceutical Industries Ltd.
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2017-2022
      • 15.13.3.2 R&D, 2017-2022
      • 15.13.3.3 Regional Market Shares, 2022
    • 15.13.4 Product Benchmarking
    • 15.13.5 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players